Prognostic value and peripheral immunologic correlates of early FDG PET response imaging in a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer

Introduction: We hypothesized that FDG PET imaging during chemoradiation for unresectable non-small cell lung cancer (NSCLC) is prognostic for survival, and that tumor PET response is correlated with peripheral T-cell function. Methods: 45 patients with AJCCv7 stage IIB-IIIB NSCLC enrolled on the phase II FLARE-RT trial and received platinum-doublet chemotherapy concurrent with 6 weeks of radiation (NCT02773238). FDG PET imaging was performed prior to treatment start and after 24 Gy of radiation (week 3). PET response status was prospectively defined by multifactorial radiologic interpretation. PET responders received 60 Gy in 30 fractions, while non-responders received concomitant boosts to 74 Gy in 30 fractions. Peripheral blood was drawn synchronously with PET imaging, from which germline DNA sequencing, T-cell receptor (TCR) sequencing, and plasma cytokines analysis were performed. Results: Median follow-up was 18.8 months, 1-year overall survival (OS) 82%, 1-year progression-free survival (PFS) 53%, and 1-year locoregional control (LRC) 88%. Higher mid-treatment PET total lesion glycolysis was detrimental to OS (1-yr 87% vs. 63%, p<0.001), PFS (1-yr 60% vs. 26%, p=0.044) and LRC (1-yr 94% vs. 65%, p=0.012), even after adjustment for clinical/treatment factors. Higher PD-L1 tumor proportion score (TPS) was correlated with PET response (p=0.017): 6/6 patients with high PD-L1 (TPS>50%) were classified as PET responders, while 4/5 patients classified as PET non-responders had negative PD-L1 (TPS<1%). Higher TCR richness and clone distribution slope was associated with improved OS (p=0.018-0.035); clone distribution slope was correlated with PET response (p=0.031). Germline DNA alterations in immunologic pathways had an outsized effect on OS and PET response; of the top 30 SNPs ranked by association with PET response status (p<0.016), a plurality (13/30) came from immunologic pathways. Conclusions: Mid-chemoradiation PET imaging is prognostic for survival; PET response may be linked to tumor and peripheral T-cell biomarkers.

[1]  S. Bowen,et al.  Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation. , 2021, Seminars in radiation oncology.

[2]  Jin Sung Kim,et al.  Predictive value of interim 18F-FDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy , 2020, PloS one.

[3]  C. Aspord,et al.  T‐cell receptor diversity as a prognostic biomarker in melanoma patients , 2020, Pigment cell & melanoma research.

[4]  S. Lim,et al.  Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer , 2020, Scientific Reports.

[5]  Nitin Ohri,et al.  18F-Fluorodeoxyglucose PET in Locally Advanced Non-small Cell Lung Cancer: From Predicting Outcomes to Guiding Therapy. , 2020, PET clinics.

[6]  Sohini Ramachandran,et al.  Germline features associated with immune infiltration in solid tumors , 2019, bioRxiv.

[7]  Helen H. W. Chen,et al.  Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy‐based 18F‐FDG PET/CT in stage III non‐small cell lung cancer , 2019, The Kaohsiung journal of medical sciences.

[8]  K. Frey,et al.  Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  J. Sonke,et al.  The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[11]  A. Bezjak,et al.  Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non–small‐cell Lung Cancer (NCT02788461) , 2018, Clinical lung cancer.

[12]  R. Ferris,et al.  T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response , 2018, Oncoimmunology.

[13]  Yufeng Shen,et al.  Quantifying size and diversity of the human T cell alloresponse. , 2018, JCI insight.

[14]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[15]  Julian C. Hong,et al.  Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  Randall K Ten Haken,et al.  Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non–Small-Cell Lung Cancer: A Phase 2 Clinical Trial , 2017, JAMA oncology.

[17]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[18]  Feng Zhang,et al.  Identification of essential genes for cancer immunotherapy , 2017, Nature.

[19]  Paul E Kinahan,et al.  Functional lung avoidance and response‐adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy , 2017, Medical physics.

[20]  Ralph R. Weichselbaum,et al.  Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.

[21]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[22]  Martin A Lodge,et al.  Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. , 2016, Radiology.

[23]  Jedd D. Wolchok,et al.  Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma , 2015, Journal of Immunotherapy for Cancer.

[24]  Fabrice Denis,et al.  Early Assessment of Metabolic Response by 18F-FDG PET During Concomitant Radiochemotherapy of Non–Small Cell Lung Carcinoma Is Associated With Survival: A Retrospective Single-Center Study , 2015, Clinical nuclear medicine.

[25]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[26]  E. Golden,et al.  Radiotherapy and immunogenic cell death. , 2015, Seminars in radiation oncology.

[27]  R. Perez-soler,et al.  Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer. , 2015, Lung cancer.

[28]  A. Chao,et al.  An improved nonparametric lower bound of species richness via a modified good–turing frequency formula , 2014, Biometrics.

[29]  You Lu,et al.  Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local Control in Non–Small-Cell Lung Cancer Receiving Radiotherapy , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  P. Brown,et al.  Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data , 2014, Breast Cancer Research and Treatment.

[31]  Helen H. W. Chen,et al.  The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  Naftali Kaminski,et al.  Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. , 2013, The Lancet. Respiratory medicine.

[33]  Brent S. Pedersen,et al.  Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis , 2013, Nature Genetics.

[34]  Timothy Daley,et al.  Predicting the molecular complexity of sequencing libraries , 2013, Nature Methods.

[35]  Philippe Lambin,et al.  Response Assessment Using 18F-FDG PET Early in the Course of Radiotherapy Correlates with Survival in Advanced-Stage Non–Small Cell Lung Cancer , 2012, The Journal of Nuclear Medicine.

[36]  S. Demaria,et al.  Role of T lymphocytes in tumor response to radiotherapy , 2012, Front. Oncol..

[37]  Nan-Tsing Chiu,et al.  Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. , 2012, Radiology.

[38]  Kristin D. Brockway,et al.  What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. , 2012, International journal of radiation oncology, biology, physics.

[39]  Benjamin Movsas,et al.  Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. , 2012, International journal of radiation oncology, biology, physics.

[40]  Baosheng Li,et al.  Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  Igor Jurisica,et al.  Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[43]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[44]  Michalis Aristophanous,et al.  The development and testing of a digital PET phantom for the evaluation of tumor volume segmentation techniques. , 2008, Medical physics.

[45]  P. McCullagh.  Estimating the Number of Unseen Species: How Many Words did Shakespeare Know? , 2008 .

[46]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[47]  D. Ettinger,et al.  Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Richard D. Wood,et al.  Human DNA Repair Genes , 2001, Science.

[49]  W. Bossert,et al.  The Measurement of Diversity , 2001 .

[50]  E. C. Pielou.  The measurement of diversity in different types of biological collections , 1966 .